Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Show detailsHide details
3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Bioatla, Inc.
A San Diego biopharmaceutical company developing antibody-based medicines for solid-tumor cancers. Its signature Conditionally Active Biologics (CAB) platform engineers antibodies to stay switched off in healthy tissue and only wake up in the acidic environment of a tumor, sparing healthy cells. Founded in 2007 by biotech veteran Jay Short and Carolyn Anderson, the firm's name plays on that same idea—antibodies that act only under certain conditions.
3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
5.07 Submission of Matters to a Vote of Security Holders
8.01 Other Events · 9.01 Financial Statements and Exhibits
2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 5.07 Submission of Matters to a Vote of Security Holders
2.02 Results of Operations and Financial Condition · 2.05 Costs Associated with Exit or Disposal Activities · 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 7.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits
8.01 Other Events
3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing · 7.01 Regulation FD Disclosure